• EPIDIOLEX®:First FDA-approved Drug Derived From Marijuana

    Share Now9sharesFacebook9Twitter0Google+Pinterest0EPIDIOLEX®:First FDA-approved Drug Derived From Marijuana GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that the U.S. Food and Drug [..]

  • FDA Approves TPOXX® :The First Drug For Smallpox

    Share Now1sharesFacebook1Twitter0Google+Pinterest0FDA Approves TPOXX® :The First Drug For Smallpox SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the U.S. Food and Drug Administration (FDA) has approved oral TPOXX® (tecovirimat) for the treatment of smallpox to mitigate the impact of a potential outbreak. TPOXX, a [..]

  • Let it rain! New coatings make natural fabrics waterproof

    Share Now1sharesFacebook1Twitter0Google+Pinterest0Let it rain! New coatings make natural fabrics waterproof MIT-developed process could offer nontoxic alternative to environmentally harmful chemicals. By: David L. Chandler | MIT News Office Fabrics that resist water are essential for everything from rainwear to military tents, but conventional water-repellent coatings have been shown to persist [..]

  • This Wireless System Can Power Devices Inside the Body

    Share Now0sharesFacebook0Twitter0Google+Pinterest0This Wireless System Can Power Devices Inside the Body By: Anne Trafton | MIT News Office  MIT researchers, working with scientists from Brigham and Women’s Hospital, have developed a new way to power and communicate with devices implanted deep within the human body. Such devices could be used to [..]

  • Novartis’s Gilenya® got Approved by FDA for Pediatric Relapsing Multiple Sclerosis

    Share Now4sharesFacebook4Twitter0Google+Pinterest0Novartis’s Gilenya® got Approved by FDA for Pediatric Relapsing Multiple Sclerosis By: Novartis News Novartis announced that the US Food and Drug Administration (FDA) has approved Gilenya® (fingolimod) for the treatment of children and adolescents 10 to less than 18 years of age with relapsing forms of multiple sclerosis (RMS), [..]

  • FDA Grants Priority Review to Genentech’s Cancer Immunotherapy Tecentriq

    Share Now3sharesFacebook3Twitter0Google+Pinterest0FDA Grants Priority Review to Genentech’s Cancer Immunotherapy Tecentriq By: Genentech News Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for TECENTRIQ® (atezolizumab), in [..]

  • First-in-World Robot-Assisted Spinal Surgery

    Share Now2sharesFacebook2Twitter0Google+Pinterest0First-in-World Robot-Assisted Spinal Surgery By: University of Pennsylvania School of Medicine Noah Pernikoff is back to his life in New York City after becoming the first patient in the world to undergo a complex three-part, robotic-assisted surgery. The robotic arms made it possible for the multidisciplinary team at Penn to [..]

  • Could robots be counsellors? Early research shows positive user experience

    Share Now2sharesFacebook2Twitter0Google+Pinterest0Could Robots be Counsellors? Early Research Shows Positive User Experience By: University of Plymouth News New research has shown for the first time that a social robot can deliver a ‘helpful’ and ‘enjoyable’ motivational interview (MI) – a counselling technique designed to support behaviour change.  Many participants in the University [..]

  • Tafinlar® + Mekinist® of Novartis Receives FDA Approval for the Treatment of BRAF V600-Mutant Melanoma

    Share Now5sharesFacebook5Twitter0Google+Pinterest0Tafinlar® + Mekinist® of Novartis Receives FDA Approval for the Treatment of BRAF V600-Mutant Melanoma By: Novartis News Novartis announced that the US Food and Drug Administration (FDA) has approved Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, [..]

  • Novartis Receives Second FDA Approval for Kymriah® to Treat B-cell Lymphoma

    Share Now48sharesFacebook47Twitter1Google+Pinterest0Novartis Receives Second FDA Approval for Kymriah® to Treat B-cell Lymphoma By: Novartis News Novartis today announced the US Food and Drug Administration (FDA) has approved Kymriah® (tisagenlecleucel) suspension for intravenous infusion for its second indication – the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after [..]

  • First Revolutionary Contact Lens Innovation of J&J Received Clearance From US-FDA

    Share Now1sharesFacebook1Twitter0Google+Pinterest0First Revolutionary Contact Lens Innovation of J&J Received Clearance From US-FDA By: Johnson & Johnson News Johnson & Johnson Vision today announced ACUVUE OASYS® with Transitions® Light Intelligent Technology™ first of its kind contact lens that provides wearers with vision correction and a dynamic photochromic filter that helps to continuously balance [..]

shares